| 1. |
|
|
| 2. |
|
|
| 3. |
|
|
| 4. |
|
|
| 5. |
- Enders, J, et al.
(författare)
-
Spectral statistics and the fine structure of the electric pygmy dipole resonance in N=82 nuclei
- 2004
-
Ingår i: Nuclear Physics, Section A. - : Elsevier BV. - 0375-9474. ; 741, s. 3-28
-
Tidskriftsartikel (refereegranskat)abstract
- We study the statistical properties of the electric pygmy dipole resonance in four different isotones with neutron number N = 82. These nuclei are Ba-138(56), Ce-140(58), Nd-142(60), (144)(62)sm. The data set comprises levels with spin and parity J(pi) = 1(-) and their ground state B(E1) transition strengths. The statistics are found to be "mixed", i.e., in between the predictions of random matrix theory for correlated and uncorrelated spectra. Moreover, we calculate spectra and transition strengths in the quasiparticle phonon model (QPM). We compare experimental and theoretical findings. The incompleteness of the data sets and its impact on the results is discussed. A consistent picture emerges which yields an improved understanding of the statistical properties of the pygmy resonance. (
|
|
| 6. |
- Elkoumy, Ahmed, et al.
(författare)
-
ACURATE neo2 Transcatheter aortic valve implantation without balloon aortic valvuloplasty : direct ACURATE neo2
- 2024
-
Ingår i: International Journal of Cardiology. - 0167-5273 .- 1874-1754. ; 400
-
Tidskriftsartikel (refereegranskat)abstract
- Background: ACURATE neo2 (Neo2) implantation is performed after systematic Balloon Aortic Valvuloplasty (BAV) in most patients. No reports exist about the feasibility and safety of direct Neo2 transcatheter aortic valve implantation (TAVI) in comparison to the standard practice. Aim: We aimed to identify the patients' baseline anatomical characteristics, procedural, and early post-procedural outcomes in patients treated using Neo2 with and without BAV. Methodology: This is a retrospective multicentre analysis of 499 patients with severe aortic stenosis who underwent TAVI using Neo2. The comparison was done according to the performance or omission of BAV. Echocardiography and computed tomography were analysed by an independent Core Lab. Propensity score matching (PSM) was performed based on the annular diameter and AV calcium volume, which identified 84 matched pairs. Results: Among the cohort included, 391 (78%) patients received BAV (BAV-yes) and 108 (22%) were not attempted (BAV-no or Direct TAVI). Patients in BAV-no cohort had smaller annular diameter (22.6 vs 23.4 mm; p < 0.001) and lower calcium volume (163 vs 581 mm3; p < 0.001) compared to BAV-yes cohort. In the matched cohort, VARC-3 device technical success was similar (95%) and all other outcome measures were statistically comparable between cohorts. Conclusion: Direct TAVI using ACURATEneo2 without pre-TAVI balloon aortic valvuloplasty in patients with mild or less valve calcifications might be feasible and associated with comparable early outcomes compared to patients with similar anatomical features undergoing systematic balloon valvuloplasty.
|
|
| 7. |
- Rück, Andreas, et al.
(författare)
-
The Early neo2 Registry : Transcatheter Aortic Valve Implantation With ACURATE neo2 in a European Population
- 2023
-
Ingår i: Journal of the American Heart Association. - 2047-9980. ; 12:15
-
Tidskriftsartikel (refereegranskat)abstract
- BACKGROUND: ACURATE neo2 is a transcatheter aortic valve implantation system consisting of a self-expanding bioprosthetic valve with supra-annular leaflet position and featuring innovations to facilitate placement accuracy and reduce paravalvular regurgitation. METHODS AND RESULTS: The goal of the Early neo2 (Early neo2 Registry of the ACURATE neo2 TAVI Prosthesis) was to gather real-life data on safety and efficacy in a European transcatheter aortic valve implantation population treated with ACURATE neo2. Data were collected from 554 consecutive patients treated with ACURATE neo2 at 12 European sites (mean age, 82 years; 66% women; mean European System for Cardiac Operative Risk Evaluation II, 4.5%±3.8%) between September 2020 and March 2021. The composite primary end point was the occurrence of any of the following: postoperative (in-hospital) paravalvular regurgitation grade ≥2, in-hospital acute kidney injury stage 3, postoperative pacemaker implantation, 30-day death, and 30-day stroke. The primary end point occurred in 12.6% of patients. The 30-day rates for all-cause death and all stroke were 1.3% and 2.7%, respectively, and 1.5% of patients exhibited stage 3 acute kidney injury. A total of 34 patients (6.2%) received a postoperative permanent pacemaker. Per core laboratory–adjudicated echocardiographic analysis, mean postoperative aortic valve gradient was 7.6±3.3 mm Hg, and 2.8% of patients exhibited paravalvular regurgitation grade ≥2. CONCLUSIONS: In this report of postmarket use of the ACURATE neo2 valve in a real-world transcatheter aortic valve implantation population, patients exhibited favorable postoperative hemodynamics and clinical outcomes and a low rate of postoperative pacemaker implantation.
|
|
